ArticleCell metabolism2020
Brain-Sparing Sympathofacilitators Mitigate Obesity without Adverse Cardiovascular Effects.
Open access · hybridAbstract read
In one paragraph
Article in Cell metabolism, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- The perineurium integrates leptin with its sympathetic outflow to protect against obesity.Nature metabolism · 2026Article
- Multidimensional Evaluation of Lisdexamfetamine: Pharmacology, Therapeutic Use, Toxicity and Forensic Implications.Basic & clinical pharmacology & toxicology · 2025Review
- Precision Medicine for Obesity Treatment.Journal of the Endocrine Society · 2025Review
- The metabolic and cardiovascular effects of amphetamine are partially mediated by the central melanocortin system.Cell reports. Medicine · 2025Article
- Neural Circuits Underlying Reciprocal Cardiometabolic Crosstalk: 2023 Arthur C. Corcoran Memorial Lecture.Hypertension (Dallas, Tex. : 1979) · 2024Article
- Gβγ-SNAP25 exocytotic brake removal enhances insulin action, promotes adipocyte browning, and protects against diet-induced obesity.The Journal of clinical investigation · 2023Article
- Article
- Dietary cysteine drives body fat loss via FMRFamide signaling in Drosophila and mouse.Cell research · 2023Article
- The sympathetic nervous system in the 21st century: Neuroimmune interactions in metabolic homeostasis and obesity.Neuron · 2022Review
- Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight loss.Obesity (Silver Spring, Md.) · 2022Review
- Article
- New practice in semaglutide on type-2 diabetes and obesity: clinical evidence and expectation.Frontiers of medicine · 2022Review
- A Tale of Three Systems: Toward a Neuroimmunoendocrine Model of Obesity.Annual review of cell and developmental biology · 2021Review
- Sympathetic Innervation of White Adipose Tissue: to Beige or Not to Beige?Physiology (Bethesda, Md.) · 2021Article
- Energy Metabolism and Aging.The world journal of men's health · 2021Review
- Unravelling novel weight loss mechanisms.Nature reviews. Endocrinology · 2020Article
- A Sympathetic Treatment for Obesity.Cell metabolism · 2020Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
25 authors at 9 institutions in 4 countries.
Inês MahúObesity Laboratory, Instituto Gulbenkian de Ciência, Oeiras 2780-156, Portugal.
Andreia BarateiroObesity Laboratory, Instituto Gulbenkian de Ciência, Oeiras 2780-156, Portugal; Neuron Glia Biology in Health and Disease, Research Institute for Medicines (iMed.ULisboa), Faculty of Pharmacy, Universidade de Lisboa, Lisbon 1649-028, Portugal.
Eva Rial-PensadoNeurObesity Group, Department of Physiology, CIMUS, University of Santiago de Compostela, Instituto de Investigación Sanitaria, Santiago de Compostela, A Coruña 15782, Spain.
Noelia Martinéz-SánchezDepartment of Physiology, Anatomy and Genetics, University of Oxford, Parks Road, Oxford OX1 3PT, UK.
Sandra H VazInstituto de Medicina Molecular, João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof., Egas Moniz, Lisbon 1649-028, Portugal; Instituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, Lisboa 1649-028, Portugal.
Pedro M S D CalInstituto de Medicina Molecular, João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof., Egas Moniz, Lisbon 1649-028, Portugal.
Benjamin JenkinsNIHR BRC Core Metabolomics and Lipidomics Laboratory, Wellcome Trust, MRL Institute of Metabolic Science, University of Cambridge, Pathology building Level 4, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.
Tiago RodriguesInstituto de Medicina Molecular, João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof., Egas Moniz, Lisbon 1649-028, Portugal.
Carlos CordeiroLaboratório de FT-ICR e Espectrometria de Massa Estrutural, Faculdade de Ciências da Universidade de Lisboa, Lisbon 1749-016, Portugal.
Miguel F CostaObesity Laboratory, Instituto Gulbenkian de Ciência, Oeiras 2780-156, Portugal; Department of Bioengineering, Instituto Superior Técnico, Universidade de Lisboa, Lisbon 1049-001, Portugal.
Raquel MendesObesity Laboratory, Instituto Gulbenkian de Ciência, Oeiras 2780-156, Portugal.
Elsa SeixasObesity Laboratory, Instituto Gulbenkian de Ciência, Oeiras 2780-156, Portugal.
Mafalda M A PereiraObesity Laboratory, Instituto Gulbenkian de Ciência, Oeiras 2780-156, Portugal.
Nadiya KubasovaObesity Laboratory, Instituto Gulbenkian de Ciência, Oeiras 2780-156, Portugal.
Vitka GresObesity Laboratory, Instituto Gulbenkian de Ciência, Oeiras 2780-156, Portugal.
Imogen MorrisObesity Laboratory, Instituto Gulbenkian de Ciência, Oeiras 2780-156, Portugal.
Carolina TemporãoObesity Laboratory, Instituto Gulbenkian de Ciência, Oeiras 2780-156, Portugal.
Marta OlivaresMicrobial Ecology, Nutrition & Health Research Unit, Institute of Agrochemistry and Food Technology, National Research Council, Valencia (IATA-CSIC), Catedratico Agustin Escardino 7, 46980, Paterna, Valencia, Spain.
Yolanda SanzMicrobial Ecology, Nutrition & Health Research Unit, Institute of Agrochemistry and Food Technology, National Research Council, Valencia (IATA-CSIC), Catedratico Agustin Escardino 7, 46980, Paterna, Valencia, Spain.
Albert KoulmanNIHR BRC Core Metabolomics and Lipidomics Laboratory, Wellcome Trust, MRL Institute of Metabolic Science, University of Cambridge, Pathology building Level 4, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK.
Francisco CorzanaDepartamento de Química, Universidad de La Rioja, Centro de Investigación en Síntesis Química, 26006 Logroño, Spain.
Ana M SebastiãoInstituto de Medicina Molecular, João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof., Egas Moniz, Lisbon 1649-028, Portugal; Instituto de Farmacologia e Neurociências, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, Lisboa 1649-028, Portugal.
Miguel LópezNeurObesity Group, Department of Physiology, CIMUS, University of Santiago de Compostela, Instituto de Investigación Sanitaria, Santiago de Compostela, A Coruña 15782, Spain.
Gonçalo J L BernardesInstituto de Medicina Molecular, João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof., Egas Moniz, Lisbon 1649-028, Portugal; Department of Chemistry, University of Cambridge, Lensfield Road, Cambridge CB2 1EW, UK. Electronic address: gb453@cam.ac.uk.
Ana I DomingosDepartment of Physiology, Anatomy and Genetics, University of Oxford, Parks Road, Oxford OX1 3PT, UK; Obesity Laboratory, Instituto Gulbenkian de Ciência, Oeiras 2780-156, Portugal; Howard Hughes Medical Institute, IGC, Oeiras, Portugal. Electronic address: ana.domingos@dpag.ox.ac.uk.
Instituto Gulbenkian de Ciência · PTUniversity of Lisbon · PTInstituto de Agroquímica y Tecnología de Alimentos · ESUniversity of Cambridge · GBAddenbrooke's Hospital · GBInstituto de Investigación Sanitaria de Santiago · ESUniversidad de La Rioja · ESUniversidade de Santiago de Compostela · ESUniversity of Oxford · GB
Funding
Biotechnology and Biological Sciences Research Council BB/M027252/1Howard Hughes Medical InstituteMedical Research Council MC_UU_00014/5Medical Research Council MC_UU_12012/5Wellcome Trust 208576Wellcome Trust 208576/Z/17/Z
Abstract
Anti-obesity drugs in the amphetamine (AMPH) class act in the brain to reduce appetite and increase locomotion. They are also characterized by adverse cardiovascular effects with origin that, despite absence of any in vivo evidence, is attributed to a direct sympathomimetic action in the heart. Here, we show that the cardiac side effects of AMPH originate from the brain and can be circumvented by PEGylation (PEGyAMPH) to exclude its central action. PEGyAMPH does not enter the brain and facilitates SNS activity via theβ
Indexed as
AmphetamineAnimalsAnti-Obesity AgentsBrainCells, CulturedFemaleMaleMiceMice, Inbred C57BLMice, TransgenicObesityAmphetamineAnti-Obesity Agentsamphetamineheat dissipationlipolysisobesitysympathetic-nervous-systemsympathofacilitatorssympathomimeticstachycardiathermogenesisthermoregulation
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.